Darbepoetin alfa administration in patients with non-Hodgkin lymphoma and chemotherapy-induced anemia receiving (±R) CHOP.

Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.

Chemotherapy-induced anemia is common in patients who have cancer. Erythropoiesis-stimulating proteins such as epoetin alfa (Procrit) and darbepoetin alfa (Aranesp) have been shown to improve hematologic and clinical outcomes in these patients. Darbepoetin alfa has a longer serum half-life than epoetin alfa, making less frequent administration possible and offering the possibility of synchroniz...

Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapy- induced anemia receiving darbepoetin alfa

Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.

Anemia is common in patients with cancer or myelodysplastic syndrome. Erythropoietic therapy offers an effective way to manage anemia by increasing hemoglobin levels, decreasing transfusion requirements, and alleviating symptoms. We reviewed data showing the feasibility and effectiveness of treatment with the erythropoiesis-stimulating protein darbepoetin alfa at extended dosing intervals to tr...

Clinical Trial Simulation of a 200-μg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia

nemia is a common complication in patients with cancer.[1,2] Anemia, defined by low hemoglobin or a low red blood cell (RBC) count, can be a consequence of the myelotoxicity of the chemotherapy regimen (especially platinum-containing regimens) or an inherent effect of the cancer itself (particularly in multiple myeloma, lymphomas, or metastatic bone disease). Although approximately 50% of patie...

Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia.

PURPOSE The safety and efficacy of extended-dosage-interval regimens of erythropoiesis-stimulating agents (ESAs) for managing chemotherapy-induced anemia (CIA) are reviewed. SUMMARY Anemia is a frequent complication of chemotherapy. The ESAs epoetin alfa and darbepoetin alfa have been shown to safely and effectively manage CIA; comparable outcomes have been demonstrated between epoetin alfa 4...